CD30在结外鼻型NK/T细胞淋巴瘤中的表达  

CD30 expression in extranodal NK/T cell lymphoma of nasal type

作　　者：陈少红[1] 伍丽琼[1] 王小拍[1] 杜洪[1] 

机构地区：[1]广州市第一人民医院病理科,广州510180

出　　处：《广州医药》2014年第5期18-20,共3页Guangzhou Medical Journal

摘　　要：目的探讨CD30在结外鼻型NK/T细胞淋巴瘤(NKTCL)中的表达及其意义。方法免疫组织化学检测CD30在30例NKTCL中的表达,同时分析CD30的表达与NKTCL临床病例特征之间的关系。结果 NKTCL CD30的表达率为30.0%(9/30);患者5年总体生存率与CD30的表达有显著关系(P=0.032);CD30表达与患者的肿瘤分级有关(P=0.035);Cox回归分析显示,CD30在统计学上可以作为独立预后指标(P=0.003)。结论 CD30的表达与NKTCL患者5年总体生存率有关,而且也许可以作为一个独立的预后指标。Objective To investigate the pathological and clinical significance of CD30 in extranodal nasal type NK/T cell lymphoma （NKTCL）. Methods We detected CD30 expression using immunohistochemistry staining in 30 cases of NK-TCL.Moreover,we analyzed the relationship between CD30 and the clinical pathological features of NKTCL. Results Our re-sults showed that CD30 expression was found in 30.0%（9 /30）;CD30 expression was associated with 5-year overall survival rate （P =0.032）as well as tumor stage （P =0.035）.Moreover,Cox regression test showed that CD30 expression were statistically independent prognostic factors for NKTCL patients（P =0.003）. Conclusion Our results suggested that 5-year overall survival rate of NKTCL patients was associated with CD30 expression which may be considered as an independent prognostic factor.

关 键 词：结外鼻型 NK/T 细胞淋巴瘤 CD30 临床病理特征 

分 类 号：R739.62[医药卫生—肿瘤]